STRC mRNA Therapy Hypothesis
Core claim
Synthetic mRNA delivered via lipid nanoparticles (LNPs) — the same platform as COVID-19 vaccines — can bypass the fundamental AAV size constraint for STRC/DFNB16 therapy. Unlike AAV, mRNA has no packaging size limit: full-length STRC mRNA (~5.3 kb coding) or RBM24 mRNA (~1.5 kb) can be encapsulated and delivered intracochlearly.
Why mRNA instead of AAV
| Property | AAV | mRNA-LNP |
|---|---|---|
| Payload size limit | ~4.7 kb total | No hard limit (10–15 kb feasible) |
| STRC CDS (5.3 kb) | Doesn’t fit | Fits |
| Genomic integration | Rare but possible | Never |
| Re-dosable | No (immune memory) | Yes (LNPs are re-dosable) |
| Immune response | Anti-capsid antibodies | Low; lipids are non-immunogenic |
| Manufacturing | Complex, slow | Fast (in vitro transcription) |
| Transient vs stable | Stable (months–years) | Transient (days–weeks per dose) |
Two delivery strategies
Strategy A — mRNA-LNP delivering RBM24 (exon-4 isoform)
Deliver synthetic mRNA encoding RBM24 including exon 4. Translated RBM24 protein then acts on endogenous STRC pre-mRNA, correcting its splicing. Works for patients where one STRC allele is intact but underexpressed.
- Payload: ~1.5 kb CDS — trivially small for mRNA
- Mechanism: upstream regulator → endogenous STRC upregulated
- Limitation: only works for hypomorphic/compound het patients with residual allele
Strategy B — mRNA-LNP delivering full-length STRC
Deliver synthetic mRNA encoding full-length STRC (5,910 nt CDS). Stereocilin protein is produced and secreted extracellularly by OHCs. No size constraint at the mRNA level.
- Payload: ~6 kb — no problem for mRNA-LNP
- Mechanism: direct replacement — works even for null alleles
- Limitation: transient expression → needs periodic re-dosing OR one-time during critical developmental window
Critical developmental window consideration
Stereocilin is a structural protein. For mRNA therapy to work in an adult patient:
- OHC survival must be sufficient (STRC loss → slow OHC degeneration)
- Enough functional OHCs remain to transfect and produce stereocilin
- Structural restoration after collapse is unproven
For Misha (or pediatric patients): earlier treatment = better OHC preservation = better outcome. If administered during the critical period (P0–P14 equivalent in humans), transient STRC expression may enable correct bundle assembly, which then persists structurally.
Why STRC is a favorable mRNA target
- Extracellular protein: secreted, can act non-cell-autonomously (neighboring untransfected OHCs may benefit)
- No transmembrane domains: no complex folding requirements
- Moderate expression level: physiological STRC expression is not extremely high — modest mRNA delivery may suffice
Computational approach
1. mRNA stability modeling
- Model half-life of synthetic mRNA in perilymph/endolymph environment
- Compare with intracellular mRNA stability in OHC cytoplasm
- Key variables: nucleoside modification (m1Ψ vs standard), secondary structure, 5’-cap efficiency
2. Dose-response for RBM24 strategy
- Build ODE model: [RBM24 mRNA dose] → [RBM24 protein level] → [STRC splicing shift] → [STRC protein level] → [stereocilia coupling restoration]
- Feed into STRC Stereocilia Bundle Mechanics Model to determine therapeutic threshold
3. LNP cochlear delivery efficiency
- Literature scan: published LNP delivery to OHC via round window injection
- Key papers: Leclere 2024 (nonviral vectors), others in sources/
- Estimate: transfection efficiency % of OHCs needed for hearing restoration
4. RBM24 isoform specificity
- Confirm exon 4-containing isoform is the therapeutic target (from Sun 2026)
- Design mRNA construct: which promoter UTR + CDS + polyA for maximal OHC translation
- Flag: RBM24 exon 4 = ~90 nt → small inclusion; synthetic mRNA must include it explicitly
5. Off-target proteome impact
- RBM24 is a global splicing regulator
- Model: if RBM24 is transiently elevated 3–5×, what other OHC transcripts are shifted?
- Data source: RBM24 eCLIP (ENCODE) intersected with OHC transcriptome
Relation to other hypotheses
- Strategy A + STRC RBM24 Regulatory Hypothesis — same target gene (RBM24), different delivery vehicle. RBM24 hypothesis uses AAV or small molecule; this uses mRNA-LNP.
- Strategy B vs STRC Mini-STRC Single-Vector Hypothesis — both deliver STRC protein. Mini-STRC truncates the gene to fit AAV; mRNA-LNP delivers full-length. Full-length is biologically preferable if delivery works.
- Both strategies vs STRC AAV Vector Design — mRNA-LNP is an alternative delivery platform, not competing with AAV at the molecular design level.
Open questions
- Can LNPs efficiently transfect OHCs via round window injection? (vs AAV which has established data)
- What mRNA dose is needed to produce therapeutic STRC protein levels?
- Is periodic re-dosing feasible in the cochlea? (immune memory for LNP is lower than AAV — likely yes)
- Does transient STRC expression (1–2 weeks) during development result in permanent structural correction?
- Is there precedent for mRNA-LNP cochlear delivery in published animal models?
Connections
[see-also]STRC RBM24 Regulatory Hypothesis — parallel hypothesis, RBM24 target, different vehicle[see-also]STRC Mini-STRC Single-Vector Hypothesis — alternative STRC replacement strategy[source]2026-04-17-sun-rbm24-strc-splicing — mechanistic basis for RBM24 strategy[see-also]Alternative STRC Delivery Hypotheses — sibling note on non-AAV delivery[see-also]STRC mRNA-LNP PKPD Multi-Dose Schedule — Strategy A multi-dose schedule: PK/PD solved, LNP delivery is the ceiling[see-also]STRC mRNA-LNP Audiogram Rescue — Strategy A clinical-endpoint projection: 20% OHC LNP targeting gives 21 dB basal recovery for Misha, 50% = AAV parity[see-also]STRC mRNA-LNP Strategy B Full-Length — Strategy B PK/PD: breaks Hill ceiling (2.18× cochlea-mean at 5% LNP), works on null alleles; required for Misha paternal 98 kb Δ[part-of]Misha-Hearing-10-Year-Plan[about]Misha
Computational results
Single-dose (2026-04-20): Min therapeutic dose (Strategy A ODE model): ~725 mRNA mol/OHC (intracellular). With 2% LNP endosomal escape: ~36,250 mol/OHC delivered. STRC peak at day 16–17. Standard LNP reaches ~96/12000 OHC — targeted LNPs needed.
Multi-dose PK/PD (2026-04-21, STRC mRNA-LNP PKPD Multi-Dose Schedule): per-OHC pharmacology solved at m1ψ Q6W × 200 mol/OHC intracellular (1,800 mol/OHC/yr intra = 90,000 mol/OHC/yr extra). Interval ceiling ≈ 42 d — beyond that STRC-protein t½ (14 d) can’t bridge the gap and trough drops below 2×. LNP delivery is the real bottleneck: cochlea-mean fold is bounded by eff × 3 + (1 − eff), so even 20% OHC targeting caps cochlea-mean at 1.4×. To breach cochlea-mean ≥ 2× requires eff ≥ 50% — no published LNP does this. Per-tonotopic-region rescue (not cochlea-mean) is the correct clinical endpoint for a structural protein.
Strategy B full-length (2026-04-21, STRC mRNA-LNP Strategy B Full-Length): direct STRC mRNA replacement (no RBM24 intermediate) breaks the Hill ceiling that blocked Strategy A. At 5% cochlear-tropic LNP, Strategy B reaches cochlea-mean 2.18× WT for Misha (Strategy A caps at 1.10× for same LNP). Cost: ~50× higher per-OHC extracellular dose (4.5M vs 90K mol/yr m1ψ Q6W) because direct translation lacks catalytic amplification. Key finding: Strategy B is the only viable mRNA option for Misha’s paternal 98 kb deletion allele — Strategy A needs pre-mRNA substrate that the deletion eliminates. Linear dose-response means dose can compensate for modest LNP tropism; delivery and dose become substitutable knobs (unlike Strategy A’s hard pharmacological ceiling). Untargeted LNP (0.8%) remains therapeutically dead for null/hypomorphic patients at any dose.
Full results: models/rbm24_mrna_dose_response_results.json + mrna_stability_cochlear_results.json + mrna_lnp_pkpd_integration.json + strc_mrna_strategy_b_pkpd.json
Experimental validation from SD03 (Sun et al. 2026)
STRC: 4 confirmed exon-skipping events when RBM24 exon-4 absent.
Strongest: 168 nt exon (chr2:121203399-121203567), inclusion drops 94%→40% (FDR 2.1e-5).
Full data: models/rbm24_sd03_splicing_analysis.json
Off-target: 469 genes affected across cochlear transcriptome — mRNA delivery of RBM24 must use minimal effective dose.